Last reviewed · How we verify
Candesartan Cilexetil in formulation 1 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Candesartan Cilexetil in formulation 1 (Candesartan Cilexetil in formulation 1) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Candesartan Cilexetil in formulation 1 TARGET | Candesartan Cilexetil in formulation 1 | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Candesartan Cilexetil in formulation 1 CI watch — RSS
- Candesartan Cilexetil in formulation 1 CI watch — Atom
- Candesartan Cilexetil in formulation 1 CI watch — JSON
- Candesartan Cilexetil in formulation 1 alone — RSS
Cite this brief
Drug Landscape (2026). Candesartan Cilexetil in formulation 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/candesartan-cilexetil-in-formulation-1. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab